{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-096171","form_type":"8-K","ticker":"ACHV","cik":"0000949858","company_name":"ACHIEVE LIFE SCIENCES, INC.","filed_at":"2024-08-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:16.474440+00:00","generated_at":"2026-05-31T09:56:10.826100+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Achieve Life Sciences Q2 net loss $8.5M; FDA Breakthrough Therapy for cytisinicline vaping cessation","bullets":["Q2 net loss $8.5M vs $8.0M prior year; cash & equivalents $61.3M as of June 30, 2024.","FDA granted Breakthrough Therapy designation for cytisinicline for nicotine e-cigarette cessation; no FDA-approved treatments exist.","Refinanced up to $20M loan with SVB; maturity extended to Dec 1, 2027 from Aug 1, 2024.","Initiated ORCA-OL trial for long-term cytisinicline exposure; over 50% of 650 participants enrolled.","Included in Russell 3000 and Russell Microcap indexes effective July 1, 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-096171","json":"https://secwatch.observer/filing/0000950170-24-096171.json","markdown":"https://secwatch.observer/filing/0000950170-24-096171.md","text":"https://secwatch.observer/filing/0000950170-24-096171.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/949858/000095017024096171/0000950170-24-096171-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/949858/000095017024096171/achv-20240813.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T09:56:10.826100+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}